Finally sent some pilots into TRU at .018 ( told them very firmly it was a recon mission, hoped they listen this time). madness or not the next year will tell. they forecast profitabilty in that time. interesting product : a test for cervical cancer that relies on electrical resisitance rather than a pap smear .Quicker, less invasive and as accurate it seems although largely chinese studies. They recently reported similar findings from the saudi clinic that was testing. Also novel is their approach being to target second and third world regions (if those are still terms), . rather than the western markets people like to see med tech companies address due to obvious geopolitical and currency risk factors. Reasons given are absence of pathology networks in existence so no competition from entrenched systems. Selling machine + consumables which I like as a model. Their annual gives you a picture of where they area at re commerialisation.
